Nuveen
CTKB icon

Nuveen’s Cytek Biosciences CTKB Stock Holding History

Nuveen’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
289,415
+43,894
+18% +$187K ﹤0.01% 2815
2026
Q1 		$1.07M Sell
245,521
-8,287
-3% -$39.1K ﹤0.01% 2559
2025
Q4 		$1.28M Hold
253,808
– – ﹤0.01% 2492
2025
Q3 		$881K Hold
253,808
– – ﹤0.01% 2681
2025
Q2 		$863K Sell
253,808
-51,177
-17% -$171K ﹤0.01% 2673
2025
Q1 		$1.22M Sell
304,985
-12,316
-4% -$63.8K ﹤0.01% 2549
2024
Q4 		$2.06M Hold
317,301
– – ﹤0.01% 2374
2024
Q3 		$1.76M Hold
317,301
– – ﹤0.01% 2482
2024
Q2 		$1.77M Buy
317,301
+11,636
+4% +$69.9K ﹤0.01% 2444
2024
Q1 		$2.05M Sell
305,665
-12,081
-4% -$95.6K ﹤0.01% 2391
2023
Q4 		$2.9M Buy
317,746
+8,436
+3% +$53.1K ﹤0.01% 2236
2023
Q3 		$1.71M Sell
309,310
-64
-0% -$513 ﹤0.01% 2365
2023
Q2 		$2.64M Sell
309,374
-625,087
-67% -$5.61M ﹤0.01% 2225
2023
Q1 		$8.59M Sell
934,461
-234,421
-20% -$2.52M ﹤0.01% 1577
2022
Q4 		$11.9M Sell
1,168,882
-171,042
-13% -$2.3M ﹤0.01% 1376
2022
Q3 		$19.7M Buy
1,339,924
+895,330
+201% +$11.6M 0.01% 1020
2022
Q2 		$4.77M Buy
444,594
+94,356
+27% +$939K ﹤0.01% 1975
2022
Q1 		$3.98M Buy
350,238
+281,263
+408% +$3.8M ﹤0.01% 2172
2021
Q4 		$1.23M Buy
68,975
+45,889
+199% +$961K ﹤0.01% 2779
2021
Q3 		$494K Buy
+23,086
New +$543K ﹤0.01% 3169

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nuveen's CTKB Position: Q2 2026 in Review

Nuveen increased its Cytek Biosciences (CTKB) stake by 18% in Q2 2026, buying an estimated $187K and bringing the position to 289,415 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2815.

Nuveen first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $19.7M in Q3 2022. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Nuveen held 289,415 shares of Cytek Biosciences worth $1.28M as of Q2 2026.
  • Nuveen bought 43,894 Cytek Biosciences shares in Q2 2026, an estimated $187K.
  • Cytek Biosciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2815 holding.
  • Nuveen first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Nuveen's Cytek Biosciences position peaked at $19.7M in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.